What Happened?
Shares of medical professional network Doximity (NYSE: DOCS) jumped 5.2% in the afternoon session after Bank of America Securities upgraded its rating on the stock from 'Neutral' to 'Buy'.
The analyst expressed a more positive outlook, citing a strategic shift in the pharmaceutical industry. Drug companies began moving advertising funds away from direct-to-consumer commercials and toward platforms that target healthcare providers directly. This pivot, influenced by changing FDA advertising regulations, placed Doximity in a strong position to capture more ad revenue. BofA expressed optimism about the company's future performance, as the trend was anticipated to gain more traction and boost growth.
After the initial pop the shares cooled down to $69.85, up 4.5% from previous close.
Is now the time to buy Doximity? Access our full analysis report here.
What Is The Market Telling Us
Doximity’s shares are very volatile and have had 28 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 5 days ago when the stock dropped 2.1% on the news that reports revealed the Trump administration is considering new restrictions on software exports to China. The news amplified investor anxiety surrounding US-China trade relations, triggering a broad sell-off in the technology sector. According to reports, the administration is weighing these limitations as a potential response to China's own trade measures. The uncertainty rattled the market, contributing to declines in major indexes like the S&P 500 and Nasdaq. Proposed export controls of this nature could significantly disrupt the global technology trade, impacting companies that rely on the Chinese market. The move adds to existing macro challenges, creating a cautious outlook among investors for the software industry.
Doximity is up 30.4% since the beginning of the year, but at $69.85 per share, it is still trading 16% below its 52-week high of $83.14 from February 2025. Investors who bought $1,000 worth of Doximity’s shares at the IPO in June 2021 would now be looking at an investment worth $1,318.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
